| Market Cap | 8.24M | P/E | - | EPS this Y | 58.20% | Ern Qtrly Grth | 11.30% |
| Income | -10.38M | Forward P/E | -0.49 | EPS next Y | 9.80% | 50D Avg Chg | -8.00% |
| Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | -22.00% |
| Dividend | N/A | Price/Book | N/A | EPS next 5Y | - | 52W High Chg | -94.00% |
| Recommedations | 2.00 | Quick Ratio | 1.49 | Shares Outstanding | 44.26M | 52W Low Chg | 19.00% |
| Insider Own | 11.81% | ROA | -209.03% | Shares Float | 39.03M | Beta | -0.26 |
| Inst Own | 2.80% | ROE | -535.10% | Shares Shorted/Prior | 193.57K/313.39K | Price | 1.04 |
| Gross Margin | - | Profit Margin | - | Avg. Volume | 75,441 | Target Price | 0.75 |
| Oper. Margin | - | Earnings Date | May 10 | Volume | 52,859 | Change | 0.97% |
Avenue Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. Its product candidates include AJ201, which is in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders. The company was incorporated in 2015 and is based in Bay Harbor Islands, Florida.
| Maxim Group | Buy | Dec 11, 23 |
| Aegis Capital | Buy | Apr 3, 23 |
| Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| ROSENWALD LINDSAY A MD | Director Director | Sep 08 | Buy | 0.72 | 348,675 | 251,046 | 354,318 | 09/12/23 |
| Fortress Biotech, Inc. | 10% Owner 10% Owner | Sep 08 | Buy | 0.72 | 418,410 | 301,255 | 1,032,390 | 09/12/23 |
| InvaGen Pharmaceuticals, Inc. | 10% Owner 10% Owner | Oct 11 | Sell | 7.714 | 388,888 | 2,999,882 | 10/13/22 |